The Festival of Hope Gala is an annual opportunity to honor individuals and organizations that have made substantial contributions to improving the lives of people affected by cancer through their partnerships with CancerCare. Oncology professionals, healthcare providers, representatives from major corporations, as well as cancer survivors and members of the community participate in this event annually. This powerful evening pays tribute to the dedicated supporters and tireless advocates who help CancerCare sustain our free programs and services.
Tickets are now available to purchase. The last day to purchase tickets is May 5, 2021.
Wednesday, May 12, 2021
6:30 p.m. Virtual Journal
7:00 p.m. Virtual Program
Many employers sponsor matching gift programs and will match any charitable contributions made by their employees. Ask your Human Resources or Benefits department if your company is eligible for matching gifts.
The impact of your gift to CancerCare may be doubled or possibly tripled!
CancerCare’s EIN # is 13-1825919
Meet Our Committee
Founded in 1944, CancerCare is the leading national organization dedicated to providing free, professional support services including case management, counseling, support groups, educational workshops, publications and financial assistance to anyone affected by cancer. All CancerCare services are provided by oncology social workers and world-leading cancer experts.
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Executive Vice President and Chief Operating Officer, Genmab US, Inc.
Mr. Mancini joined Genmab in March 2020 as Executive Vice President and Chief Operating Officer. He is responsible for ensuring Genmab brings its innovative and differentiated medicines to patients around the world and for leading Genmab’s Commercial, Corporate Development, Business Development and Information Technology functions. Prior to joining Genmab, Mr. Mancini served in a variety of strategic and operational leadership roles over a nearly 24-year career at Bristol Myers Squibb (BMS). Most recently, he led BMS’ US Innovative Medicines Unit, a team of over 1100 people focused on Immunology & Cardiovascular diseases.
He holds a Bachelor of Science in Biochemistry from the University of Ottawa, Canada, an M.B.A. from Clemson University, South Carolina, USA, and participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France.
All sponsorships and tickets are 100% tax deductible.
The last day to purchase tickets is May 5, 2021.
Feel free to reach out to Special Events Director, Erica Lebensberg,
with any questions: